Physician profile
David E Johnson
NPI 1780781302
$10,676.38
in general payments reported to CMS, 2019-2025
26 companies · $3,095 in 2025
The $3,095 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,509 · 2022: $2,187 · 2023: $2,080 · 2024: $1,804 · 2025: $3,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,811 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,811.01 |
| Education | $168.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,889.90 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,795.66 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,378.03 | 2021-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $879.52 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $720.54 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $590.00 | 2021-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $564.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $433.88 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $243.91 | 2022-2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $196.80 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $150.66 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $133.71 | 2025 | Givlaari |
| Novo Nordisk INC | $124.53 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $110.21 | 2021-2023 | Dificid, Zinplava |
| Qol Medical, LLC | $86.02 | 2021-2025 | Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $68.90 | 2021-2022 | |
| Pfizer INC. | $62.69 | 2023-2025 | |
| Braintree Laboratories, INC. | $54.97 | 2021-2022 | |
| Organon LLC | $42.02 | 2022-2023 | Renflexis, Hadlima |
| Lilly USA, LLC | $30.66 | 2025 | Omvoh |
| Capsovision, INC. | $28.39 | 2024 | Capsocam Plus |
| Celgene Corporation | $26.48 | 2022 | |
| Aimmune Therapeutics, INC. | $20.19 | 2024 | |
| Echosens North America, INC. | $17.52 | 2024 | Fibroscan |
| Exact Sciences Corporation | $15.85 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.